The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, an initiative intended to deepen regulatory understanding and provide practical support to developers in one of the country's fastest-growing medtech segments.
Published on the MHRA's official blog, the announcement describes a coordinated effort to help innovators navigate regulatory expectations, improve compliance and move safe, effective digital mental health products into clinical use. According to the agency, the move responds to growing demand for clarity on evidence requirements, post-market responsibilities and the evolving regulatory landscape for software-based and AI-enabled mental health tools.
A forum for shared learning across the sector
The community is designed to bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a common understanding of best practice. As the field widens, from therapeutic applications to AI-supported assessment tools, the agency argues that consistent, practical guidance has become more urgent.
Four objectives are set out:
- helping developers interpret regulatory requirements and build compliance into product design at an earlier stage;
- identifying challenges shared by innovators, particularly small and medium-sized enterprises entering the mental health space;
- sharing real-world experience from organisations already working through regulatory pathways;
- strengthening dialogue between industry and regulators so that emerging technologies meet expectations on safety, performance and evidence.
For the wider medtech development community, the agency presents the community as a route to engage directly with the regulator on questions that often determine whether a promising technology reaches patients.
Survey to shape initial priorities
To set the community's early work, the MHRA has opened a survey for digital mental health technology developers and other stakeholders across the medtech ecosystem. It asks about current regulatory challenges, where clearer guidance would help, and how compliance support could be improved.
The agency is seeking broad participation so that the community reflects real-world needs rather than top-down assumptions. For developers, the survey is framed as a direct channel for influencing future regulatory support and for helping to create a more predictable, transparent environment for innovation.
The MHRA is encouraging readers to complete the survey and to circulate it within their organisations, arguing that a strong response will help ensure the community delivers practical, meaningful support that accelerates safe and effective innovation for patients.
The announcement did not set out how organisations can join the community, what form its activities will take, or when it will begin operating.